BiomX (NYSEAMERICAN:PHGE) Issues Earnings Results

BiomX (NYSEAMERICAN:PHGE) posted its earnings results on Wednesday. The company reported ($0.37) EPS for the quarter, FiscalAI reports.

BiomX Stock Performance

Shares of PHGE stock traded up $0.00 on Wednesday, reaching $0.14. The stock had a trading volume of 587,849 shares, compared to its average volume of 3,744,429. BiomX has a 1 year low of $0.12 and a 1 year high of $12.29. The stock has a market cap of $1.61 million, a P/E ratio of -0.04 and a beta of 1.35. The company has a 50 day simple moving average of $0.29 and a 200 day simple moving average of $2.25.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in BiomX stock. Citadel Advisors LLC purchased a new stake in shares of BiomX Inc. (NYSEAMERICAN:PHGE) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned 0.61% of BiomX as of its most recent SEC filing. 40.57% of the stock is owned by institutional investors and hedge funds.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.